Related Experiment Videos

Some observations on dimethylformamide hepatotoxicity

Toxicology
|January 1, 1981
PubMed

Insights

Dimethylformamide (DMF) and monomethylformamide (MMF) cause liver damage in rats, indicated by elevated sorbitol dehydrogenase (SDH) levels. MMF appears to be the primary hepatotoxic agent, with DMF potentially delaying its effects.

Area of Science:

  • Toxicology
  • Hepatology
  • Biochemistry

Background:

  • Dimethylformamide (DMF) is a widely used industrial solvent.
  • Understanding the toxicity and metabolic pathways of DMF is crucial for occupational safety.
  • Biotransformation products, such as monomethylformamide (MMF) and formamide (F), may contribute to DMF's toxic effects.

Purpose of the Study:

  • To investigate the hepatotoxicity of DMF and its biotransformation products, MMF and F, in a rat model.
  • To correlate serum sorbitol dehydrogenase (SDH) levels and liver histology with DMF, MMF, and F administration.
  • To elucidate the role of MMF in DMF-induced liver injury.

Main Methods:

  • Rats were administered DMF, MMF, or F intraperitoneally at specific doses.
  • Serum SDH levels were measured at 3-hour intervals from 9 to 30 hours post-administration.
  • Liver histology was examined at 12, 21, and 30 hours to assess necrosis.

Main Results:

  • DMF (479 mg/kg) elevated SDH at 27 and 30 hours; a lower dose (240 mg/kg) showed effects from 15 hours.
  • MMF (387 mg/kg) consistently elevated SDH levels throughout the study period.
  • Formamide (F) did not cause significant SDH elevation.
  • Simultaneous administration of DMF and MMF delayed the onset of elevated SDH levels.

Conclusions:

  • Hepatotoxicity of DMF is likely mediated by MMF, a biotransformation product.
  • MMF is a potent hepatotoxic agent, causing elevated SDH levels.
  • DMF may exert a protective or delaying effect on MMF-induced hepatotoxicity.

Related Concept Videos